Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

43.70 -0.51 (-1.15%)
Official Closing Price Updated: 7:00 PM EDT, May 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 15,961,995
Open 44.36
Bid (Size) 43.70 (4)
Ask (Size) 43.74 (5)
Prev. Close 44.21
Today's Range 43.33 - 44.42
52wk Range 43.33 - 68.99
Shares Outstanding 2,222,113,553
Dividend Yield 5.22%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases 
From Editas Medicine, Inc.
Via GlobeNewswire
3 Top ETFs to Buy for Passive Income in May
These ETFs provide investors with above-average income streams. 
Via The Motley Fool
Topics ETFs

Performance

YTD
-17.17%
-17.17%
1 Month
-17.53%
-17.53%
3 Month
-10.58%
-10.58%
6 Month
-14.78%
-14.78%
1 Year
-35.83%
-35.83%

More News

Read More
A Closer Look at Bristol-Myers Squibb's Options Market Dynamics
Via Benzinga
How Is The Market Feeling About Bristol-Myers Squibb?
Via Benzinga
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
Via Benzinga
Topics Stocks
Exposures US Equities
Why Bristol Myers Squibb Stock Is Sinking Today
Via The Motley Fool
Last Week's Worst-Performing Stocks: Are These 10 Large-Cap Stocks In Your Portfolio? (April 21-27, 2024)
Via Benzinga
Peeling Back The Layers: Exploring Bristol-Myers Squibb Through Analyst Insights
Via Benzinga
Stock Market Rebounds; Tesla, Microsoft, Google, Meta, Chipotle, GE In Focus: Weekly Review
Via Investor's Business Daily
CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
From Bristol Myers Squibb
Via Business Wire
Investor Sentiment Improves Slightly, But Dow Tumbles Over 350 Points
Via Benzinga
Topics Stocks
Exposures US Equities
Crude Oil Moves Higher; Bristol Myers Squibb Shares Fall After Q1 Results
Via Benzinga
Exposures Fossil Fuels
Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Bristol Myers Squibb Swings To Quarterly Loss, After String Of Multi-Billion Acquisitions
Via Benzinga
PLTR Stock: Palantir Beefs Up Healthcare AI Work Through Parexel Deal
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
BMY Stock Earnings: Bristol-Myers Squibb Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Bristol-Myers Squibb Layoffs 2024: What to Know About the Latest BMY Job Cuts
Via InvestorPlace
Topics Workforce
Exposures Layoff
Bristol Myers Squibb (BMY) Q1 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Is Bristol Myers Squibb Stock a Millionaire Maker?
Via The Motley Fool
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
Via Investor's Business Daily
AstraZeneca, Sanofi Jump On First-Quarter Earnings; Bristol Myers Lags
Via Investor's Business Daily
Bristol Myers Squibb Reports First Quarter Financial Results for 2024
From Bristol Myers Squibb
Via Business Wire
Novartis Stock Gains On European Drugmaker's Q1 Earnings Surprise, Lifts Annual Outlook
Via Benzinga
5 Crash-Proof Stocks to Buy Immediately
Via InvestorPlace
US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.